Michael Weickert

Company: Pacylex Pharmaceuticals, Inc.

Job title: Chief Executive Officer

Seminars:

How Clinical Signals From Oral Zelenirstat Apply to NMT Inhibitors as ADC Payloads: Leveraging Validated Mechanisms & a Known Safety Profile 11:15 am

Discussing clinical data from FIC oral NMT inhibitor, zelenirstat, including survival benefits in patients with solid tumors and clinical response in lymphoma, that support the mechanism’s therapeutic potential Preliminary analysis of an extensive portfolio of potent NMTi ADC candidates Preliminary examination of in vitro ADC data on the potential NMTi-ADC activity against cancer cell linesRead more

day: Conference Day Two